Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: Comparison between patients with versus without stroke

Stroke

Volumn 45, Issue 10, 2014, Pages 2983-2988

  Yoon, Chang Hyo ^a   Park, Yoon Kyung ^a   Kim, Suk Jae ^a   Lee, Mi Ji ^a   Ryoo, Sookyung ^a   Kim, Gyeong Moon ^a   Chung, Chin Sang ^a   Lee, Kwang Ho ^a   Kim, June Soo ^a   Bang, Oh Young ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

atrial fibrillation; randomized trial; stroke; warfarin

Indexed keywords

CREATININE; WARFARIN; ANTICOAGULANT AGENT; APIXABAN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; DABIGATRAN; EDOXABAN; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; RIVAROXABAN; THIAZOLE DERIVATIVE; THIOPHENE DERIVATIVE;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BLEEDING TENDENCY; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; COHORT ANALYSIS; COMPARATIVE STUDY; CREATININE CLEARANCE; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PATIENT PARTICIPATION; PATIENT PREFERENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RANKIN SCALE; RETROSPECTIVE STUDY; TRANSIENT ISCHEMIC ATTACK; ANALOGS AND DERIVATIVES; COMPLICATION; FEMALE; MALE; METHODOLOGY; STROKE;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; FEMALE; HUMANS; MALE; MORPHOLINES; PYRAZOLES; PYRIDINES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; STROKE; THIAZOLES; THIOPHENES; WARFARIN;

EID: 84922480892     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.005599     Document Type: Article

References (18)

1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
2. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
3. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.
4. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-2104.
5. Maasland L, van Oostenbrugge RJ, Franke CF, Scholte Op Reimer WJ, Koudstaal PJ, Dippel DW; Netherlands Stroke Survey Investigators. Patients enrolled in large randomized clinical trials of antiplatelet treatment for prevention after transient ischemic attack or ischemic stroke are not representative of patients in clinical practice: The Netherlands Stroke Survey. Stroke. 2009;40:2662-2668.
6. Fonville AF, Samarasekera N, Hutchison A, Perry D, Roos YB, Al-Shahi Salman R. Eligibility for randomized trials of treatments specifically for intracerebral hemorrhage: community-based study. Stroke. 2013;44:2729-2734.
7. Joppi R, Cinconze E, Mezzalira L, Pase D, Poggiani C, Rossi E, et al; Italian Horizon Scanning Project. Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: A population-based study. Eur J Intern Med. 2013;24:318-323.
8. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236-239.
9. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58:395-401.
10. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest. 2010;138:1093-1100.
11. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A metaanalysis of randomised trials. Lancet. 2014;383:955-962.
12. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719-2747.
13. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al; RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206-1214.
14. Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost. 2011;106:968-977.
15. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363-2372.
16. Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32:2387-2394.
17. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33:2821-2830.
18. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al; J-ROCKET AF Study Investigators. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation-the J-ROCKET AF study. Circ J. 2012;76:2104-2111.